Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Analysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes

Marek Trněný, Laura Fogliatto, Faithlore Gardner, Ian Flinn, Jean-François Larouche, Corinne Haioun, Miguel Canales, Hideki Goto, Roman Hajek, Gilles Salles, Avrita Singh, Mark Yan, Rucha Kothari, Gabriel Man, Deniz Sahin, Jamie Hirata, Calvin Lee, Hervé Tilly, Christopher R. Flowers

Blood Adv (2025) 9 (13): 3263–3267.

https://doi.org/10.1182/bloodadvances.2024014695

Published: 2025

Journal Articles

A Phase 2 Study of Obinutuzumab Combined with Lenalidomide in Previously Untreated High Tumor Burden Follicular Lymphoma

Blood Adv bloodadvances.2025016483.

https://doi.org/10.1182/bloodadvances.2025016483

Published: 2025

Includes: Supplemental data

Journal Articles

Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel

Blood Adv bloodadvances.2024014476.

https://doi.org/10.1182/bloodadvances.2024014476

Published: 2025

Includes: Supplemental data

Journal Articles

Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas

Blood Adv (2025) 9 (7): 1485–1491.

https://doi.org/10.1182/bloodadvances.2024014635

Published: 2025

Journal Articles

Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium

Blood Adv (2025) 9 (5): 1013–1023.

https://doi.org/10.1182/bloodadvances.2024014053

Published: 2025

Includes: Supplemental data

Journal Articles

American Society of Hematology: building a comprehensive minority recruitment and retention professional program

Margo R. Rollins, Rahma M. Warsame, Melody Smith, Arturo Molina, Rayne H. Rouce, Belinda R. Avalos, Cage S. Johnson, Jose A. Lopez, Alexis A. Thompson, Lisa Fanning, Patricia Frustace, Keelin Roche, Nathalie van Havre, Devon Mack, Christopher R. Flowers, Deirdra R. Terrell

Blood Adv (2024) 8 (24): 6237–6247.

https://doi.org/10.1182/bloodadvances.2024013519

Published: 2024

Journal Articles

Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL

Arushi Khurana, Raphael Mwangi, Loretta J. Nastoupil, Patrick M. Reagan, Umar Farooq, Jason T. Romancik, Timothy J. McDonnell, Shaun M. Riska, lzidore S. Lossos, Brad S. Kahl, Peter Martin, Thomas E. Witzig, James R. Cerhan, Christopher R. Flowers, Grzegorz S. Nowakowski, Matthew J. Maurer

Blood Adv (2024) 8 (16): 4414–4422.

https://doi.org/10.1182/bloodadvances.2024012838

Published: 2024

Includes: Supplemental data

Journal Articles

Impact of patient demographics and neighborhood socioeconomic variables on clinical trial participation patterns for NHL

Chijioke Nze, Clark R. Andersen, Amy A. Ayers, Jason Westin, Michael Wang, Swaminathan Iyer, Sairah Ahmed, Chelsea Pinnix, Francisco Vega, Lynne Nguyen, Lorna McNeill, Loretta J. Nastoupil, Kehe Zhang, Cici X. Bauer, Christopher R. Flowers

Blood Adv (2024) 8 (14): 3825–3837.

https://doi.org/10.1182/bloodadvances.2023011040

Published: 2024

Includes: Supplemental data

Journal Articles

Defining primary refractory large B-cell lymphoma

Blood Adv (2024) 8 (13): 3402–3415.

https://doi.org/10.1182/bloodadvances.2024012760

Published: 2024

Includes: Supplemental data

Journal Articles

Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib

Javid J. Moslehi, Richard R. Furman, Constantine S. Tam, Joe-Elie Salem, Christopher R. Flowers, Aileen Cohen, Meng Zhang, Jun Zhang, Lipeng Chen, Han Ma, Jennifer R. Brown

Blood Adv (2024) 8 (10): 2478–2490.

https://doi.org/10.1182/bloodadvances.2023011641

Published: 2024

Includes: Supplemental data

Journal Articles

Randomized, double-blinded, placebo-controlled trial of allogeneic cord blood T-regulatory cells for treatment of COVID-19 ARDS

Douglas E Gladstone, Franco D'Alessio, Christopher Howard, Mi-Ae Lyu, Jason R. Mock, Kevin W. Gibbs, Darryl Abrams, Meixian Huang, Ke Zeng, James P. Herlihy, Sergio T. Castillo, Roland Bassett, Tara Sadeghi, Simrit Parmar, Christopher R. Flowers, Siddhartha Mukherjee, David Schoenfeld, Peter F. Thall, Arthur S. Slutsky

Blood Adv (2023) 7 (13): 3075–3079.

https://doi.org/10.1182/bloodadvances.2022009619

Published: 2023

Journal Articles

Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma

Blood Adv (2023) 7 (11): 2287–2296.

https://doi.org/10.1182/bloodadvances.2022009225

Published: 2023

Includes: Supplemental data

Journal Articles

A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL

Blood Adv (2023) 7 (7): 1137–1145.

https://doi.org/10.1182/bloodadvances.2022008174

Published: 2023

Journal Articles

Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysis

Danny Luan, Tolulope Fatola, Ahmed Toure, Christopher R. Flowers, Brian Link, Jonathan W. Friedberg, Jonathon B. Cohen, Brad Kahl, Izidore S. Lossos, Loretta Nastoupil, Matthew J. Maurer, James R. Cerhan, Peter Martin

Blood Adv (2022) 6 (15): 4413–4423.

https://doi.org/10.1182/bloodadvances.2022007687

Published: 2022

Includes: Supplemental data

Journal Articles

SIRPα + macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab

Blood Adv (2022) 6 (11): 3286–3293.

https://doi.org/10.1182/bloodadvances.2022007104

Published: 2022

Includes: Supplemental data

Journal Articles

Day 30 SUV max predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy

Ajlan Al Zaki, Lei Feng, Grace Watson, Sairah A. Ahmed, Haleigh Mistry, Loretta J. Nastoupil, Misha Hawkins, Ranjit Nair, Swaminathan P. Iyer, Hun J. Lee, Raphael E. Steiner, Christopher R. Flowers, Elizabeth J. Shpall, Partow Kebriaei, Sattva S. Neelapu, Jason R. Westin, Paolo Strati

Blood Adv (2022) 6 (9): 2867–2871.

https://doi.org/10.1182/bloodadvances.2021006715

Published: 2022

Includes: Supplemental data

Journal Articles

Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey

Blood Adv (2022) 6 (9): 2745–2756.

https://doi.org/10.1182/bloodadvances.2021006504

Published: 2022

Includes: Supplemental data

Journal Articles

Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement

Blood Adv (2022) 6 (7): 2267–2274.

https://doi.org/10.1182/bloodadvances.2021005602

Published: 2022

Includes: Supplemental data

Journal Articles

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data

Laurie H. Sehn, Mark Hertzberg, Stephen Opat, Alex F. Herrera, Sarit Assouline, Christopher R. Flowers, Tae Min Kim, Andrew McMillan, Muhit Ozcan, Violaine Safar, Gilles Salles, Grace Ku, Jamie Hirata, Yi Meng Chang, Lisa Musick, Matthew J. Matasar

Blood Adv (2022) 6 (2): 533–543.

https://doi.org/10.1182/bloodadvances.2021005794

Published: 2022

Includes: Supplemental data

Journal Articles

Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy

Blood Adv (2021) 5 (23): 5179–5189.

https://doi.org/10.1182/bloodadvances.2021004765

Published: 2021

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Analysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes

A Phase 2 Study of Obinutuzumab Combined with Lenalidomide in Previously Untreated High Tumor Burden Follicular Lymphoma

Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel

Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas

Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium

American Society of Hematology: building a comprehensive minority recruitment and retention professional program

Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL

Impact of patient demographics and neighborhood socioeconomic variables on clinical trial participation patterns for NHL

Defining primary refractory large B-cell lymphoma

Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib

Randomized, double-blinded, placebo-controlled trial of allogeneic cord blood T-regulatory cells for treatment of COVID-19 ARDS

Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma

A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL

Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysis

SIRPα + macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab

Day 30 SUV max predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy

Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey

Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data

Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only